A low pH level in silages opens the epicyte
fractions by increasing acid hydrolysis of hemicellulose .
The patent from the United States Patent and Trademark Office, number 6,852,319, is entitled, "Method of Use of Transgenic Plant Expressed Antibodies." It was issued to The Scripps Research Institute, where the technology was developed, and exclusively licensed to Epicyte
Pharmaceutical which was acquired by Biolex in 2004.
The production of pharmaceuticals from plants has been targeted by a number of large companies, including Monsanto and Syngenta, as well as small companies such as Epicyte
, Ventria BioSciences and Meristem Therapeutics.
Epicyte Pharmaceutical, Inc., a San Diego biopharmaceutical company focused on the discovery and development of human monoclonal antibodies in plant manufacturing models, has announced that its scientists have identified the first pair of fully human antibodies capable of neutralizing the Clostridium difficile (C.
Epicyte plans to use its plant-based antibody manufacturing technology to produce the C.
El 9 de enero de 2001, la compania biotecnologica Epicyte
(San Diego, Estados Unidos), socio corporativo de la multinacional Dow Chemicals, declaro al diario ingles The Observater: "Tenemos un invernaculo lleno de plantas de maiz que estan produciendo anticuerpos espermicidas ...
Dow also has agreement with Epicyte
Pharmaceutical for the development of monoclonal antibodies in transgenic plants.
(5.) A genetically engineered "contraceptive corn" has been developed by Epicyte
, a company in San Diego, California.
The antibody DNA is "coded" into the crop, according to San Diego biotech firm Epicyte
. The antibodies, which work by sticking to viruses and stopping them from entering cells, could protect from herpes, genital warts and even HIV, according to New Scientist magazine.
The San Diego-based EPIcyte
has partnered with Dow Chemical to develop and produce experimental human antibodies in plants, as well as a topical contraceptive and a microbicide that is purported to be active against HIV.
Whaley and Larry Zeitlin of Epicyte
Pharmaceuticals in San Diego, also in the October NATURE BIOTECHNOLOGY.
will use this technology to produce its antibody pipeline and to address capacity constraints in the antibody-based therapeutics market which is estimated to reach $8 billion by 2004.